ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 802 • 2017 ACR/ARHP Annual Meeting

    Sensorineural Hearing Loss in Takayasu’s Arteritis

    Ugur Kimyon1, Sinem Nihal Esatoglu1, Ebru Kara2, Ahmet Atas2, Elif Emel Gunay2, Emine Deniz Gozen2, Emin Karaman2, Vedat Hamuryudan1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul, Turkey

    Background/Purpose: Sensorineural hearing loss has been reported to be increased in several chronic autoimmune and non-autoimmune diseases such as systemic lupus erythematosus (SLE), progressive systemic…
  • Abstract Number: 803 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis

    Helin Masyan, Sinem Nihal Esatoglu, Ayse Merve Celik, Vedat Hamuryudan, Hasan Yazici and Emire Seyahi, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: In addition to the occlusive vasculitis, hypertension and accelerated atherosclerosis are probably risk factors of the cardiovascular complications in Takayasu arteritis (TA). Although, management…
  • Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting

    The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate

    Manami Hirata1, Akiko Ueno2, kazuyuki fujita2, Nobuyuki Shibutou2 and Masahiro Yamamura3, 1Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, 2Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, 3Okayama Saiseikai General Hospital, Okayama, Japan

    Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
  • Abstract Number: 805 • 2017 ACR/ARHP Annual Meeting

    Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis

    Andrea Gloor1, Daniel Yerly2, Stefan Kuchen3, Sabine Adler4, Stephan Reichenbach1, Michael Seitz5 and Peter M. Villiger6, 1Rheumatology, University hospital, Bern, Switzerland, 2Rheumatology, Uiversity hospital, Bern, Switzerland, 3Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, MD, Switzerland, 4Rheumatology, University Hospital Bern, Bern, Switzerland, 5Rheumatology, Clinical Immunology & Allergology, University Hospital, Bern, Switzerland, 6Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland

    Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) about tocilizumab (TCZ) in giant cell arteritis (GCA) showed…
  • Abstract Number: 806 • 2017 ACR/ARHP Annual Meeting

    Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database

    Eishi Uechi and Kiyohide Fushimi, Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

    Background/Purpose: The giant cell arteritis (GCA) management requires the administration of high-dose glucocorticoid (GC) at the introduction remission and the gradual reduction of the dosage.…
  • Abstract Number: 807 • 2017 ACR/ARHP Annual Meeting

    B Cells in Giant Cell Arteritis: a Novel Target for Treatment?

    Jacoba C. Graver1, Maria Sandovici2, Wayel H. Abdulahad2, Erlin A. Haacke3, Annemieke M.H. Boots2 and Elisabeth Brouwer4, 1Rheumatoloy and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 4Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) is the most common type of systemic vasculitis. Currently, two forms of GCA are described: a cranial(C)-GCA (temporal arteritis) and…
  • Abstract Number: 808 • 2017 ACR/ARHP Annual Meeting

    Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort

    Anthony Sammel1, Katherine Nguyen2, Susan Smith3, Christopher Little3, Janice Brewer2 and Rodger Laurent2, 1Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Royal North Shore Hospital, St Leonards, Sydney, Australia, 3Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, Sydney, Australia

    Background/Purpose: Recent studies have suggested that giant cell arteritis (GCA) may be triggered by reactivation of varicella zoster virus (VZV) based on high rates of…
  • Abstract Number: 809 • 2017 ACR/ARHP Annual Meeting

    Prevalence and Distribution of Vascular FDG Uptake on Positron Emission Tomography (PET)-CT in Patients Suspected of Having Giant Cell Arteritis – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Study

    Anthony Sammel1, Edward Hsiao2, Katherine Nguyen3, Geoffrey Schembri2, Leslie Schrieber3, Peter Youssef4, Beatrice Janssen3 and Rodger Laurent3, 1Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, 2Royal North Shore Hospital, St Leonards, Australia, 3Royal North Shore Hospital, St Leonards, Sydney, Australia, 4Royal Prince Alfred Hospital, Camperdown, Sydney, Australia

    Background/Purpose: Positron emission tomography (PET)-CT scan can assess large vessel vasculitis in giant cell arteritis (GCA). It has a reported sensitivity of 80% for biopsy…
  • Abstract Number: 810 • 2017 ACR/ARHP Annual Meeting

    Sensitivity of Temporal Artery Biopsy in Giant Cell Arteritis: Systematic Literature Review and Meta-Analysis of Clinical Data

    Emma Rubenstein1, Carla Maldini2, Solange Gonzalez-Chiappe3, Sylvie Chevret4 and Alfred Mahr3, 1Internal medicine, University Hospital Saint-Louis, Paris, France, 2Rheumatology, Hospital Córdoba, Cordoba, Argentina, 3Internal Medicine, University Hospital Saint-Louis, Paris, France, 4Biostatistics, University Hospital Saint-Louis, Paris, France

    Background/Purpose: Temporal artery biopsy (TAB) is a reference test for establishing a diagnosis of giant cell arteritis (GCA). A subset of patients with a clinical…
  • Abstract Number: 811 • 2017 ACR/ARHP Annual Meeting

    The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis

    Nazanin Naderi1,2, Aladdin Mohammad3,4,5, Minna Willim4,6, Jan-Åke Nilsson1,6 and Carl Turesson1,6, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Rheumatology, Danderyd Hospital, Stockholm, Sweden, 3Department of Renal Medicine, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, 4Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 5Department of Rheumatology, Skåne University Hospital, Lund, Sweden, 6Department of Rheumatology, Skåne University Hospital, Malmö, Sweden

    Background/Purpose: Giant cell arteritis (GCA) is a systemic disease with extensive vascular involvement. The mechanisms underlying the diversity of GCA phenotypes are incompletely understood. The…
  • Abstract Number: 812 • 2017 ACR/ARHP Annual Meeting

    Mortality Risk and Cause-Specific Mortality in Polymyalgia Rheumatica: A Population-Based Cohort Study

    Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: To determine mortality risk in polymyalgia rheumatic (PMR) and compare cause-specific mortality rates among patients with PMR to age- and sex-matched comparators from the…
  • Abstract Number: 813 • 2017 ACR/ARHP Annual Meeting

    Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study

    Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: To determine the incidence, time trends and, severity of herpes zoster in a population-based incidence cohort of patients with polymyalgia rheumatic (PMR) compared to…
  • Abstract Number: 814 • 2017 ACR/ARHP Annual Meeting

    Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides

    Cécile-Audrey Durel1, Arnaud Hot2, Ludovic Trefond3, Olivier Aumaître4, Grégory Pugnet5, Maxime Samson6, Sébastien Abad7, Alexandre Belot8, Claire Blanchard-Delaunay9, Pascal Cathebras10, Pascal Cohen11, Fleur Cohen12, Vincent Cottin13, Bruno Crestani14, Stéphanie Dumonteil15, Claire de Moreuil16, Stéphane Durupt17, Jean-Gabriel Fuzibet18, Margaux Garzaro-regard19, Nicolas Girszyn20, Bertrand Godeau21, Eric Hachulla22, Yvan Jamilloux23, Patrick Jego24, Estibaliz Lazaro25, Thomas Le Gallou26, Eric Liozon27, Thierry Martin28, Thomas Papo29, Antoinette Perlat26, Pascal Pillet30, Karim Sacre31, Pascal Sève32, Loïc Guillevin for the French Vasculitis Study Group33 and Benjamin Terrier11, 1Internal Medicine, Hôpital Edouard Herriot, lyon, France, 2Internal Medicine, Hopital Edouard Herriot, Lyon, France, 3Internal medicine, CHU Gabriel-Montpied, clermont-ferrand, France, 4CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 5Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, 6Dijon University Hospital, Dijon, France, 7Internal medicine, Hôpital Avicennes, avicennes, France, 8Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, 9Internal Medicine, Centre Hospitalier, Niort, France, 10Internal Medicine, University Hospital St Etienne, St Etienne, France, 11Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, 12Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 13Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, 14Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, 15Internal medicine, CHU de Limoges, Limoges, France, 16CHU de Brest, Brest, France, 17Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, 18Internal medicine, Hôpital l'Archet, Nice, France, 19Internal medicine, CHU de Nice, Nice, France, 20CHU de Rouen, Rouen, France, 21Internal medicine, Hôpital Henri-Mondor, Créteil, France, 22CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, 23Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 24Medecine Interne, CHU Rennes, Rennes, France, 25service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, 26Internal medicine, CHU de Rennes, Rennes, France, 27Departement of Internal Medicine, Limoges University Hospital, Limoges, France, 28Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, 29Paris Bichat, Paris, France, 30Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, 31Department of Internal Medicine, Bichat Hospital, Paris, France, 32Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 33Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France

    Background/Purpose: Orbital mass is a rare ophthalmologic manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) that remains a therapeutic challenge. This study aimed to describe…
  • Abstract Number: 815 • 2017 ACR/ARHP Annual Meeting

    Incidence in Large Vessel GCA in Northern Italy during a 11-Year Period

    Luigi Boiardi1, Giovanna Restuccia2, Pierluigi Macchioni3, Pamela Mancuso4, Mariagrazia Catanoso5, Francesco Muratore6, Filippo Crescentini1, Giulia Pazzola1, Nicolò Pipitone1 and Carlo Salvarani7, 1Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, 2Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, 3Rheumatology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 4Interinstitutional Epidemiology Unit, Azienda USL di Reggio Emilia (Local Health Authority) and Azienda Ospedaliera IRCCS di Reggio Emilia,, Reggio Emilia, Italy, 5Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 6Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 7Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy

    Background/Purpose: there are few studies regarding the incidence of large vessel GCA (LV GCA). Purpose: to investigate the incidence in patients diagnosed with large vessel…
  • Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting

    Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab

    Nuria Vegas-Revenga1, Javier Loricera1, Antonio Mera2, Eva Pérez- Pampín2, Santos Castañeda3, Lucia C. Domínguez-Casas1, José Luis Martín-Varillas4, Belén Atienza-Mateo4, MC Gonzalez-Vela1, Jose L. Hernández5, Miguel Angel González-Gay4 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, 3Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, 4Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 5Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
  • « Previous Page
  • 1
  • …
  • 1257
  • 1258
  • 1259
  • 1260
  • 1261
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology